Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Pelthos Therapeutics Inc.AMEX: PTHS
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns negative
Q1 FY2026 other non-cash items was -$2.02M, compared with $94.21K a year earlier. Trailing-twelve-month other non-cash items was $21.42M. Over 3 fiscal years it compounded at +458.3% a year.
Context
- Other non-cash items amounted to 145.5% of revenue in FY2025.
- Other non-cash items increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near -$2.02M or moves back toward the trailing-twelve-month quarterly average of $5.36M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 24.44M USD
- Year-over-year change
- +7330.5%
- 3-year CAGR
- +458.3%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.44M | +7330.5% |
| FY2024 | 2024-12-31 | 328.93K | -87.4% |
| FY2023 | 2023-12-31 | 2.62M | +1762.5% |
| FY2022 | 2022-12-31 | 140.43K | — |
Other Non-Cash Items vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's LTM Mar 2026 other non-cash items of $21.42M is the 2nd largest of the 4 companies compared; the peer median is $1.16M.
- Its year-over-year change of +11840.0% is the highest of 4, against a peer median of +100.3%.
- Other non-cash items amounts to 77.3% of revenue for PTHS.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $1.25B | -201192.5% | — | — | |
| LTM Mar 2026 | $21.42M | +11840.0% | +458.3% | 77.3% | |
| LTM Mar 2026 | $4.34M | +100.3% | +68.7% | — | |
| LTM Mar 2026 | $1.16M | +1388.0% | — | — | |
| Peer median (excluding PTHS) | $1.16M | +100.3% | +68.7% | — | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Depreciation & Amortization | 0 | 0 | 0 | 2.36M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 0 |
| Change in Working Capital | 640.86K | 2.05M | 34.63K | (6.07M) |
| Accounts Receivables | 0 | 0 | (45.79K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 1.78M |
| Accounts Payables | 413.6K | 1.63M | 1.18M | 1.36M |
| Other Working Capital | 227.26K | 424.07K | (1.1M) | (395K) |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 24.44M |
| Operating Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.59M) |
| Capital Expenditures | 0 | 0 | 0 | (99K) |
| Acquisitions (Net) | 0 | 0 | 0 | (5.14M) |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (5.24M) |
| Debt Repayment | 400K | 766.94K | 321.43K | 17.75M |
| Common Stock Issued | 0 | 255.41K | 6.05M | 27.59M |
| Common Stock Repurchased | 0 | 0 | (166.51K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.02M | 6.21M | 45.34M |
| Effect of Forex Changes | 0 | 0 | 0 | (443) |
| Net Change in Cash | 55.07K | 41.32K | 417.05K | 17.51M |
| Free Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.69M) |
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.